Arun Sudhaman

Working the angles around media, comms and marketing.

Novartis picks Cohn & Wolfe for global heart failure portfolio

leave a comment »

Posted to the Holmes Report here

Novartis has assigned PR duties for its global heart failure portfolio to Cohn & Wolfe, following a review that featured several healthcare agencies.

The Holmes Report understands that Novartis is hoping to expand its range of heart failure drugs in light of the increasing competition faced by the rest of its lucrative cardiovascular portfolio. The six-figure brief covers strategy and brand vision for two heart failure products that are expected to launch in 2014.

Novartis’ current cardiovascular portfolio is led by $6 billion heart pressure medication Diovan, which began facing generic competition last year. It is currently developing two heart failure drugs – LCZ696 and RLX030 – and also acquired another late-stage heart failure drug – Relaxin – last year. The Swiss pharmaceutical giant also produces high blood pressure drugs Exforge and Tekturna/Rasilez.

It is understood that other agencies involved in the pitch included Chandler Chicco and Ruder Finn.

Neither Novartis nor Cohn & Wolfe responded to request for comment.


Written by Arun Sudhaman

March 21, 2011 at 4:49 pm

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: